Targeted Treatment of the Rheumatic Diseases E-Book , livre ebook

Targeted Treatment of the Rheumatic Diseases
First Edition

Michael H. Weisman, MD
Director, Division of Rheumatology, Cedars-Sinai Medical Center
Professor of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

Michael E. Weinblatt, MD
John R. and Eileen K. Riedman Professor of Medicine, Harvard Medical School, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts

James S. Louie, MD
Professor Emeritus of Medicine, Division of Rheumatology at CHS, David Geffen School of Medicine at UCLA, Los Angeles, California

Ronald F. van Vollenhoven, MD, PhD
Senior Rheumatologist, Karolinska University Hospital
Associate Professor of Rheumatology, The Karolinska Institute, Stockholm, Sweden
Elsevier Inc., 2010
Saunders
Copyright
1600 John F. Kennedy Blvd.
Ste 1800
Philadelphia, PA 19103-2899
TARGETED TREATMENT OF THE RHEUMATIC DISEASES
ISBN: 978-1-4160-9993-2
Copyright © 2010 by Saunders, an imprint of Elsevier Inc.
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Rights Department: phone: (+1) 215 239 3804 (US) or (+44) 1865 843830 (UK); fax: (+44) 1865 853333; e-mail: healthpermissions@elsevier.com. You may also complete your request on-line via the Elsevier website at http://www.elsevier.com/permissions .

Notice
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on their own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editors assumes any liability for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this book.
The Publisher
Cover photos:
Panel 2
The top figure shows TNF in its active trimer form with the monomers colored individually. Receptor binding occurs along the three monomer interfaces. The left figure models the TNF soluble receptor fusion protein comprised of two TNF receptor arms with their TNF binding sites (bright blue) attached to an Fc of IgG1 (cyan). The right figure models the TNF monoclonal antibodies with a complete IgG1 structure including the Fc (cyan) and its complementarity-determining regions which bind TNF (CDRs in bright blue).
Courtesy of the Journal of Investigative Dermatology Symposium Proceedings, volume 12, number 1, May 2007.
Library of Congress Cataloging-in-Publication Data
Targeted treatment of the rheumatic diseases / [edited by] Michael H. Weisman … [et al.]. -- 1st ed.
p. ; cm.
Includes bibliographical references and index.
ISBN 978-1-4160-9993-2 (alk. paper)
1. Rheumatism--Treatment. 2. Arthritis--Treatment.
I. Weisman, Michael H.
[DNLM: 1. Rheumatic Diseases--drug therapy.
2. Arthritis, Rheumatoid--drug therapy. WE 544 T1852 2009]
RC927.T37 2009
616.7’23--dc22 2009007823
Acquisitions Editor: Pamela Hetherington
Design Direction: Steven Stave
Marketing Manager: Courtney Ingram
Printed in China
Last digit is the print number: 9 8 7 6 5 4 3 2 1
Dedication
This book is dedicated to our wonderful patients whose determination sustains us, and to our rheumatology colleagues whose devotion to the field energizes us.
As the understanding of pathogenic molecules and pathways, new genetics, and environmental triggers unfolds, our hope is that the use of targeted therapies for specific sub-populations of patients will bring us closer to the goal of optimal care for each and all.
We salute the engaged and knowledgeable clinician who will apply the subtleties of effective and prudent targeted therapies to the daily practice of rheumatology, hoping that this volume may help in that momentous task.
Contributors

Helene Alexanderson, PhD, RPT, Rheumatology Unit, Department of Medicine, The Karolinska Institute, Orthopedic/Rheumatology Unit, Department of Physical Therapy, Karolinska University Hospital, Solna, Stockholm, Sweden, Targeted Treatment of the Idiopathic Inflammatory Myopathies

Ralf Baron, MD, Sektion für Neurologische Schmerzforschung und Therapie, Klinik für Neurologie, Christian-Albrechts-Universität zu Kiel, Kiel, Germany, Mechanisms and Treatment Strategy of Complex Regional Pain Syndromes

Francis Berenbaum, MD, PhD, Professor, University Pierre and Marie Curie, Head, Department of Rheumatology, Assistance Publique Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France, Management of Osteoarthritis: Pharmacotherapy

Joel A. Block, MD, The Willard L. Wood, MD Professor, and Director, Section of Rheumatology, Rush Medical College, and Rush University Medical Center, Chicago, Illinois, Regional Disorders of the Neck, Shoulder, Arm, and Hand

Hendrika Bootsma, MD, PhD, Associate Professor of Rheumatology, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands, Management of Sjögren’s Syndrome

David G. Borenstein, MD, Clinical Professor of Medicine, The George Washington University Medical Center, Washington, DC, Management of Mechanical Lumbar Spine Disease

Johan Bratt, MD, PhD, Associate Professor, and Head, Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Management of Medium and Small Vessel Vasculitis, Including the Antineutrophil Cytoplasmic Antibody–Associated Diseases

Vivian P. Bykerk, MD, FRCP(C), Assistant Professor of Medicine, University of Toronto, Director, Early Arthritis Program, and Assistant Director, Division of Advanced Therapeutics, Rebecca MacDonald Center for Arthritis and Autoimmune Disease, Staff Rheumatologist, Mount Sinai Hospital, University Health Network, Staff, Multidisciplinary Osteoporosis Program, Women’s College Hospital, Toronto, Ontario, Canada, Management of Rheumatoid Arthritis: The Newly Diagnosed Patient

Grant W. Cannon, MD, Professor of Medicine, Division of Rheumatology, Department of Internal Medicine, University of Utah School of Medicine, Associate Chief of Staff for Academic Affiliations, George E. Whalen Veterans Affairs Medical Center, Salt Lake City, Utah, Management of Sarcoidosis, Behçet’s Disease, and Other Rare Rheumatic Diseases

Hiok Hee Chng, MBBS(Singapore), MMed(Internal Medicine), FRCP(Glasg), Clinical Professor, Yong Loo Lin School of Medicine, National University Singapore, Senior Consultant, Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Principles in Management of Systemic Lupus Erythematosus

Leslie J. Crofford, MD, Gloria W. Singletary Professor of Internal Medicine, and Chief, Division of Rheumatology and Women’s Health, University of Kentucky, Lexington, Kentucky, Management of Fibromyalgia and Unexplained Generalized Pain Syndromes

Maryam Dastmalchi, MD, PhD, Senior Consultant, Rheumatology Unit, Department of Medicine, The Karolinska Institute, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, Targeted Treatment of the Idiopathic Inflammatory Myopathies

William P. Docken, MD, Assistant Professor of Medicine, Harvard Medical School, Associate Physician, Brigham and Women’s Hospital, Boston, Massachusetts, Polymyalgia Rheumatica and Giant Cell Arteritis

Doruk Erkan, MD, Assistant Professor of Medicine, Weill Medical College of Cornell University, Associate Physician-Scientist, The Barbara Volcker Center for Women and Rheumatic Disease, Assistant Attending Physician, Division of Rheumatology, Hospital for Special Surgery, New York, New York, Management of the Antiphospholipid Syndrome

Michael G. Feely, MD, Rheumatology Fellow, Section of Rheumatology and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, Management of Established Rheumatoid Arthritis

Dafna D. Gladman, MD, FRCP(C), Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research Institute, and Director, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada, Management of Psoriatic Arthritis

Merete Lund Hetland, MD, PhD, Associate Research Professor, University of Copenhagen, Copenhagen, Consultant in Rheumatology, Department of Rheumatology, Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, Management of Rheumatoid Arthritis: Principles and Strategies for Antirheumatic Pharmacotherapy

Marc C. Hochberg, MD, MPH, Professor of Medicine and Epidemiology and Preventive Medicine, and Head, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, Maryland, Osteoporosis

Norman T. Ilowite, MD, Professor of Pediatrics, Albert Einstein College of Medicine, Division Chief, Pediatric R